Efficacy versus safety: The dilemma of using novel platelet inhibitors for the treatment of patients with ischemic stroke and coronary artery disease

Research output: Contribution to journalArticle

Abstract

Coronary and cerebrovascular atherothrombosis are the leading cause of mortality and morbidity worldwide. Novel antiplatelet agents have been established for the management of patients with clinically evident coronary atherothrombosis and are increasingly used in these patients. These agents, however, have shown limited Efficacy in the prevention of cerebrovascular events and potential harm in patients with history of stroke or transient ischemic attack. Herein, the Efficacy and safety of two established antiplatelet agents in patients with stroke - aspirin and clopidogrel - are reviewed with a focus on the use and challenges related to novel antiplatelet agents - prasugrel, ticagrelor, and vorapaxar - in patients at risk for and with a history of stroke or transient ischemic attack.

Original languageEnglish
Pages (from-to)321-329
Number of pages9
JournalTherapeutics and Clinical Risk Management
Volume10
Issue number1
DOIs
Publication statusPublished - 2014

Keywords

  • Aspirin
  • Cerebrovascular disease
  • Clopidogrel
  • Coronary artery disease
  • Novel antiplatelet agents

ASJC Scopus subject areas

  • Pharmacology (medical)
  • Medicine(all)
  • Pharmacology, Toxicology and Pharmaceutics(all)
  • Safety Research
  • Chemical Health and Safety

Fingerprint Dive into the research topics of 'Efficacy versus safety: The dilemma of using novel platelet inhibitors for the treatment of patients with ischemic stroke and coronary artery disease'. Together they form a unique fingerprint.

  • Cite this